
European Journal of Medicinal Chemistry p. 789 - 797 (1998)
Update date:2022-07-29
Topics:
Dal Piaz, Vittorio
Giovannoni, Maria Paola
Castellana, Carla
Palacios, Jose Maria
Beleta, Jorge
Domenech, Teresa
Segarra, Victor
A novel group of heterocyclic-fused 3(2H)-pyridazinones were synthesized and evaluated as PDE III and PDE IV inhibitors and their affinity for 3H Rolipram high affinity binding site was determined. The obtained data demonstrated that some of the new compounds are endowed with potent and selective PDE IV inhibitory activity and greatly attenuated affinity for the Rolipram high affinity binding site that seems to be responsible for unwanted effects. Theoretical calculations, performed on representative compounds, demonstrated the presence of three hydrogen-bonding acceptor regions, of which one looks quite different with respect to literature compounds. This finding could explain the different pharmacological profile of the title compounds with respect to the analogs reported in the literature.
View MoreContact:+86-15995924277
Address:WuZhongOu suzhou new south road 89
Contact:+86-371-86058576
Address:NO.32, Jingsan Road, Zhengzhou, China
Wuhan Sunrise Pharmaceutical Technology Co., Ltd
Contact:+86-27-83314682
Address:Room 340, New material Industrial base No.17, Gu Tian Five Lu , Qiaokou District, Wuhan , China
Jurong Huaheng Natural Biological Products Factory
website:http://www.risebiochem.com
Contact:+86-13921007726
Address:Chuncheng town,Jurong city,Jiangsu province,China
Anhui New Star Pharmaceutical Development Co., Ltd
Contact:013956922763
Address:Floor 3, F9A, F Workshop, No.110 Kexue Road, High-Tech Development Zone, Hefei, Anhui ,China
Doi:10.1021/ja00149a011
(1995)Doi:10.1016/j.tetlet.2014.03.004
(2014)Doi:10.1055/s-1994-25545
(1994)Doi:10.1016/j.tet.2014.03.037
(2014)Doi:10.1039/c4cc00857j
(2014)Doi:10.1016/j.molcata.2014.01.005
(2014)